NCT07253142
A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
Version history last read from ClinicalTrials.gov on Aug 29, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Enrollment closed, study ongoing
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 1 to 10
- Start date changed from estimate of Jan 14, 2026 to Feb 5, 2026
- Notable Eligibility criteria expanded, about 24 wordsv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (4)
Arms and interventions
Patients with good tolerability and well controlled disease will receive the treatment once every 3 weeks (Q3W), until disease progression, initiation of a new anti-tumor therapy, death, emergence of intolerable toxicity, or withdrawal of informed consent (whichever occurs first).
Patients with good tolerability and well controlled disease will receive the treatment once every 3 weeks (Q3W), Until disease progression, initiation of a new anti-tumor therapy, death, emergence of intolerable toxicity, or withdrawal of informed consent (whichever occurs first)
Drugs: HLX43 dose 1, HLX43 dose 2
Sites
10 sites in 1 country